Tango Therapeutics Inc
Q3 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.55%.
Did TNGX Beat Earnings? Q3 2025 Results
Tango Therapeutics delivered a stunning earnings reversal in Q3 2025, swinging to a profit of $0.13 per diluted share against a consensus estimate of negative $0.07, a beat of 287.32%, while revenue surged 363.6% year over year to $53.81 million, clearing the $41.24 million analyst estimate by 30.47%. The single engine behind those numbers was a one-time accounting event: the truncation of Tango's collaboration agreement with Gilead triggered full recognition of all remaining deferred upfront and research option-extension payments, collapsing what had been a $29.17 million net loss in Q3 2024 into net income of $15.88 million. Crucially, milestones and royalty rights on licensed programs remain intact. Looking ahead, the company enters 2026 with a focused pipeline led by vopimetostat in MTAP-deleted cancers, a pivotal pancreatic cancer trial expected to launch next year, and a cash runway extending into 2028 following a $212 million net-proceeds equity offering completed in October 2025, providing ample runway to reach those catalysts.
- Recognition of all remaining deferred revenue from Gilead collaboration truncation drove Q3 2025 revenue to $53.8 million
- Reduced R&D expenses from discontinuation of TNG908 and TNG348 programs
- Lower G&A expenses from decreased personnel-related and external legal/patent costs
“We are wrapping up 2025 with significant momentum, supported by our recent disclosure of vopimetostat clinical data, supporting the potential of this compound to be a turning point for treatment of multiple difficult-to-treat MTAP-del cancers, beginning with pancreatic cancer.”
Tango Therapeutics CEO, on the earnings call
Forward Guidance & Outlook
Tango expects a strong cadence of value-creating milestones in 2026, including: initiation of a pivotal trial for vopimetostat in second-line MTAP-deleted pancreatic cancer; initial safety and efficacy data from combination trials of vopimetostat with Revolution Medicines' RAS(ON) inhibitors (daraxonrasib and zoldonrasib); a vopimetostat monotherapy lung cancer data update; and initial safety and efficacy data from the TNG456 Phase 1/2 trial in glioblastoma. The October 2025 financing of $225 million in gross proceeds, yielding approximately $212 million in net proceeds, extends the company's cash runway into 2028.
TNGX YoY Financials
TNGX Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.